Relevant conflicts of interest/financial disclosures: G.U.H. is supported by the Deutsche Forschungsgemeinschaft (HO2402/6-1). E.G. is partially funded by the Spanish Ministerio de Economia y Competitividad, Programa de Técnicos de Apoyo 2011, and received a research grant from the Academia de Ciencies Mediques de Catalunya 2011.
Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy
Version of Record online: 21 FEB 2013
Copyright © 2013 Movement Disorder Society
Volume 28, Issue 4, pages 504–509, April 2013
How to Cite
Respondek, G., Roeber, S., Kretzschmar, H., Troakes, C., Al-Sarraj, S., Gelpi, E., Gaig, C., Chiu, W. Z., van Swieten, J. C., Oertel, W. H. and Höglinger, G. U. (2013), Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov. Disord., 28: 504–509. doi: 10.1002/mds.25327
Full financial disclosures and author roles may be found in the online version of this artcle.
- Issue online: 8 APR 2013
- Version of Record online: 21 FEB 2013
- Manuscript Accepted: 26 NOV 2012
- Manuscript Revised: 31 OCT 2012
- Manuscript Received: 3 JUL 2012
- progressive supranuclear palsy;
- clinical diagnostic criteria;
Autopsy is the diagnostic gold standard for progressive supranuclear palsy (PSP). The National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of “probable” PSP are thought to possess high specificity and low sensitivity. The NINDS-SPSP criteria for “possible” PSP are considered to increase sensitivity at the expense of specificity. The Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) criteria are intended to improve sensitivity while maintaining high specificity. The aim of this study was to conduct a clinicopathological evaluation of the NINDS-SPSP and NNIPPS criteria in tertiary neurological centers. Defined clinical features and their year of onset were recorded by chart review in neuropathologically diagnosed patients with PSP, Parkinsons's disease (PD), MSA parkinsonism and corticobasal degeneration from four European brain banks. Fulfilment of the clinical diagnostic criteria was verified for each year after disease onset and for the final antemortem record. We analyzed 98 PSP patients and 46 disease controls. The NINDS-SPSP “probable” criteria yielded shorter time to diagnosis, slightly higher specificity and positive predictive value (PPV), and similar sensitivity, compared with the NNIPPS criteria. Unexpectedly, the NINDS-SPSP “possible” criteria yielded the lowest sensitivity, specificity, and PPV. A combination of NINDS-SPSP possible and probable criteria yielded the highest sensitivity. We suggest that the NINDS-SPSP probable criteria might be preferred for recruitment of patients for clinical trials, where an early and specific diagnosis is important. For routine clinical care, where high sensitivity is crucial, a combination of NINDS possible and probable criteria might be preferred. © 2013 Movement Disorder Society